Estrella Immunopharma, Inc. (NASDAQ:ESLA) has announced a major milestone in its STARLIGHT-1 Phase I/II clinical trial, ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...

Memorial Sloan Kettering Cancer Center investigators report that T cell interferon-γ (IFNγ) orchestrates a ...

A compound found in nearly every energy drink may also be feeding aggressive blood cancers. Researchers discovered that leukemia cells absorb taurine to grow faster — and extra taurine only made ...

CD70 expression increased cytotoxicity of CD70 CAR NK cells against osteosarcoma; however, upregulation of CD70 had no effect on cytotoxicity.

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic ...

Researchers at the National University of Singapore have developed a scalable, non-viral technology that efficiently delivers ...

GTBP announces completion of dosing in Cohort 1 and start of dosing in Cohort 2 of Phase 1 trial for GTB-3650, showing ...